Abstract:Key PointsHistone deacetylase inhibitors are novel anticancer agents that induce tumour cell death, differentiation, and/or cell cycle arrest. As well as their intrinsic effects on tumour cells, histone deacetylase inhibitors may additionally affect neoplastic growth and survival by regulating host immune responses and tumour vasculature.The pleiotropic cellular effects of HDACi can act cooperatively to mediate potent anti-tumour activities; however, the molecular processes underlying these effects of HDACi remain to be fully elucidated.The activity of diverse non-histone proteins can be regulated by acetylation indicating that HDACi may have a much broader effect on cellular physiology than originally understood. Altered gene expression through the effects of HDACi on the activity of transcription factors and transcription-independent effects of HDACi are also important in their anticancer activities.In preclinical studies, several classes of HDACi have been found to have potent anticancer activities, and some have demonstrated promising therapeutic potential in early clinical trials for haematological malignancies such as cutaneous T-cell lymphoma, myelodysplastic syndromes and diffuse B-cell lymphoma.While HDACi show promise as single agent anticancer drugs, their use in combination with other agents may prove to be their most useful application. Already, HDACi have been shown to function synergistically with a host of structurally and functionally diverse chemical compounds and biologically active polypeptides.

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

New Development of HDAC Inhibitors As Anti-Cancer Agents

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy

Targeting histone deacetylases for cancer therapy: Trends and challenges

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Advances in targeting histone deacetylase for treatment of solid tumors

Anticancer activities of histone deacetylase inhibitors

Histone Deacetylase Inhibitors as Anticancer Drugs

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

HDACi: molecular mechanisms and therapeutic implications in the innate immune system

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

Discovery and Development of HDAC Inhibitors: Approaches for the Treatment of Cancer a Mini-review

HDAC11: A novel target for improved cancer therapy

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Histone deacetylases and cancer: causes and therapies

HDAC7: a promising target in cancer